GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shandong Boan Biotechnology Co Ltd (HKSE:06955) » Definitions » Net Current Asset Value

Shandong Boan Biotechnology Co (HKSE:06955) Net Current Asset Value : HK$-0.62 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Shandong Boan Biotechnology Co Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Shandong Boan Biotechnology Co's net current asset value per share for the quarter that ended in Dec. 2023 was HK$-0.62.

The historical rank and industry rank for Shandong Boan Biotechnology Co's Net Current Asset Value or its related term are showing as below:

During the past 4 years, the highest Price-to-Net-Current-Asset-Value Ratio of Shandong Boan Biotechnology Co was 141.43. The lowest was 141.43. And the median was 141.43.

HKSE:06955's Price-to-Net-Current-Asset-Value is not ranked *
in the Biotechnology industry.
Industry Median: 3.88
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Shandong Boan Biotechnology Co Net Current Asset Value Historical Data

The historical data trend for Shandong Boan Biotechnology Co's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Boan Biotechnology Co Net Current Asset Value Chart

Shandong Boan Biotechnology Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Net Current Asset Value
-0.78 0.93 0.14 -0.62

Shandong Boan Biotechnology Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Current Asset Value Get a 7-Day Free Trial 0.93 0.34 0.14 -0.36 -0.62

Competitive Comparison of Shandong Boan Biotechnology Co's Net Current Asset Value

For the Biotechnology subindustry, Shandong Boan Biotechnology Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shandong Boan Biotechnology Co's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shandong Boan Biotechnology Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Shandong Boan Biotechnology Co's Price-to-Net-Current-Asset-Value falls into.



Shandong Boan Biotechnology Co Net Current Asset Value Calculation

Shandong Boan Biotechnology Co's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(A: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(779.872-1097.627-0-0)/509.278
=-0.62

Shandong Boan Biotechnology Co's Net Current Asset Value (NCAV) per share for the quarter that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(Q: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(779.872-1097.627-0-0)/509.278
=-0.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shandong Boan Biotechnology Co  (HKSE:06955) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Shandong Boan Biotechnology Co Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Shandong Boan Biotechnology Co's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Shandong Boan Biotechnology Co (HKSE:06955) Business Description

Traded in Other Exchanges
Address
No. 39 Keji Avenue, High-Tech Industrial Development Zone, Shandong Province, Yantai, CHN
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. The company is engaged in the development, manufacture, and commercialization of high-quality biologics in China and around the world. It focuses on areas such as oncology, metabolism, autoimmunity, and ophthalmology. Geographically company's revenue is generated from customers located in Mainland China.
Executives
Asiapharm Investments Ltd.
Ginkgo (ptc) Limited
Liu Dianbo
Luye Life Sciences Group Ltd
Luye Pharma Holdings Ltd.
Luye Pharma Hong Kong Limited
Luye Pharmaceutical International Co., Ltd.
Luye Pharmaceutical Investment Co., Ltd.
Nelumbo Investments Limited
Shorea Lbg
Luye Pharma Group Ltd.
Shan Dong Lv Ye Zhi Yao You Xian Gong Si
Yan Tai Lv Ye Yi Yao Kong Gu Ji Tuan You Xian Gong Si
Li Li 2201 Interest of corporation controlled by you

Shandong Boan Biotechnology Co (HKSE:06955) Headlines

No Headlines